An2 therapeutics inc ANTX.US 總覽分析
ANTX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分低，若以價值投資為目標且有長期投資部位，需要嚴格執行自己的出場計畫來減持部位
ANTX 近期報酬表現
-0.83%
An2 therapeutics inc
4.57%
同產業平均
3.26%
S&P500
與 ANTX 同產業的標的表現
- INBX Inhibrx biosciences inc價值 -趨勢 2 分波段 2 分籌碼 2 分股利 1 分查看更多
ANTX 公司資訊
AN2 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.